DaVita Inc. (NYSE:DVA) Receives Average Rating of “Hold” from Analysts

Shares of DaVita Inc. (NYSE:DVA) have been given an average rating of “Hold” by the five brokerages that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $161.80.

Several equities analysts have recently commented on the company. Truist Financial upped their target price on DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a research report on Monday, October 7th. UBS Group boosted their price target on DaVita from $169.00 to $175.00 and gave the company a “buy” rating in a research note on Thursday, August 8th. Bank of America boosted their price target on DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a research note on Wednesday, August 7th. Barclays boosted their price target on DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a research note on Thursday. Finally, TD Cowen boosted their price target on DaVita from $139.00 to $150.00 and gave the company a “hold” rating in a research note on Wednesday, July 24th.

DaVita Price Performance

DaVita stock opened at $139.81 on Friday. DaVita has a 12 month low of $76.17 and a 12 month high of $168.50. The stock’s 50 day moving average is $157.96 and its 200-day moving average is $145.97. The company has a current ratio of 1.16, a quick ratio of 1.12 and a debt-to-equity ratio of 9.94. The company has a market capitalization of $11.73 billion, a price-to-earnings ratio of 14.89, a PEG ratio of 0.90 and a beta of 0.87.

DaVita (NYSE:DVA) last posted its earnings results on Tuesday, October 29th. The company reported $2.59 EPS for the quarter, missing the consensus estimate of $2.76 by ($0.17). DaVita had a net margin of 6.86% and a return on equity of 77.00%. The firm had revenue of $3.26 billion during the quarter, compared to analyst estimates of $3.25 billion. During the same period in the previous year, the company posted $2.85 EPS. DaVita’s revenue for the quarter was up 4.6% compared to the same quarter last year. Equities research analysts expect that DaVita will post 9.99 EPS for the current year.

Insiders Place Their Bets

In other DaVita news, CEO Javier Rodriguez sold 50,000 shares of the company’s stock in a transaction on Monday, September 16th. The stock was sold at an average price of $165.05, for a total transaction of $8,252,500.00. Following the completion of the sale, the chief executive officer now directly owns 837,835 shares in the company, valued at $138,284,666.75. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other DaVita news, CEO Javier Rodriguez sold 50,000 shares of the company’s stock in a transaction on Monday, September 16th. The stock was sold at an average price of $165.05, for a total transaction of $8,252,500.00. Following the completion of the sale, the chief executive officer now directly owns 837,835 shares in the company, valued at $138,284,666.75. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Joel Ackerman sold 64,029 shares of the stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $155.06, for a total value of $9,928,336.74. Following the completion of the transaction, the chief financial officer now owns 111,481 shares of the company’s stock, valued at $17,286,243.86. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 173,482 shares of company stock worth $27,387,069 over the last three months. Insiders own 2.00% of the company’s stock.

Institutional Trading of DaVita

A number of large investors have recently bought and sold shares of the business. Financial Strategies Group Inc. grew its holdings in DaVita by 19.2% during the 3rd quarter. Financial Strategies Group Inc. now owns 3,135 shares of the company’s stock worth $507,000 after acquiring an additional 504 shares during the period. QRG Capital Management Inc. grew its holdings in DaVita by 5.0% during the 3rd quarter. QRG Capital Management Inc. now owns 4,577 shares of the company’s stock worth $750,000 after acquiring an additional 216 shares during the period. Asset Management One Co. Ltd. grew its stake in shares of DaVita by 4.7% in the 3rd quarter. Asset Management One Co. Ltd. now owns 19,629 shares of the company’s stock valued at $3,218,000 after buying an additional 886 shares during the period. Forum Financial Management LP acquired a new stake in shares of DaVita in the 3rd quarter valued at about $221,000. Finally, Janney Montgomery Scott LLC grew its stake in shares of DaVita by 16.4% in the 3rd quarter. Janney Montgomery Scott LLC now owns 24,591 shares of the company’s stock valued at $4,031,000 after buying an additional 3,468 shares during the period. 90.12% of the stock is currently owned by institutional investors and hedge funds.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.